International Journal of Cancer Management

Published by: Kowsar

Evaluation of Involvement of Axillary Lymph Nodes with Ki-67 Expression in Patients with Breast Cancer

Mahdi Asadi 1 , Aghigh Ziaeemehr 1 , Soodabeh Shahidsales 2 , * , Seyed Amir Aledavood 2 , Kazem Anvari 2 , Marjan Mirsadraee 3 , Maryam Nemati 1 , Amir Avan 4 and Elaheh Aghel 1
Authors Information
1 Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2 Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
3 Reza Oncology Center, Mashhad, Iran
4 Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Article information
  • International Journal of Cancer Management: August 2018, 11 (8); e66567
  • Published Online: August 8, 2018
  • Article Type: Research Article
  • Received: January 22, 2018
  • Revised: June 24, 2018
  • Accepted: August 1, 2018
  • DOI: 10.5812/ijcm.66567

How to Cite: Asadi M, Ziaeemehr A, Shahidsales S, Aledavood S A, Anvari K , et al. Evaluation of Involvement of Axillary Lymph Nodes with Ki-67 Expression in Patients with Breast Cancer, Int J Cancer Manag. 2018 ; 11(8):e66567. doi: 10.5812/ijcm.66567.

Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Siegel R, Jemal A. Cancer facts & figures. Atlanta: American Cancer Society, Inc; 2013.
  • 2. Kolahdoozan S, Sadjadi A, Radmard AR, Khademi H. Five common cancers in Iran. Arch Iran Med. 2010;13(2):143-6. [PubMed: 20187669].
  • 3. Sadjadi A, Nouraie M, Mohagheghi MA, Mousavi-Jarrahi A, Malekezadeh R, Parkin DM. Cancer occurrence in Iran in 2002, an international perspective. Asian Pac J Cancer Prev. 2005;6(3):359-63. [PubMed: 16236000].
  • 4. Harirchi I, Ebrahimi M, Zamani N, Jarvandi S, Montazeri A. Breast cancer in Iran: a review of 903 case records. Public Health. 2000;114(2):143-5. doi: 10.1038/ [PubMed: 10800155].
  • 5. Harirchi I, Karbakhsh M, Kashefi A, Momtahen AJ. Breast cancer in Iran: results of a multi-center study. Asian Pac J Cancer Prev. 2004;5(1):24-7. [PubMed: 15075000].
  • 6. Rezaianzadeh A, Peacock J, Reidpath D, Talei A, Hosseini SV, Mehrabani D. Survival analysis of 1148 women diagnosed with breast cancer in Southern Iran. BMC Cancer. 2009;9:168. doi: 10.1186/1471-2407-9-168. [PubMed: 19497131]. [PubMed Central: PMC2699348].
  • 7. Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, et al. Breast cancer in Iran: an epidemiological review. breast j. 2007;13(4):383-91.
  • 8. Cole KD, He HJ, Wang L. Breast cancer biomarker measurements and standards. Clin Appl. 2013;7(1-2):17-29.
  • 9. Apostolou G, Apostolou N, Biteli M, Kavantzas N, Patsouris E, Athanassiadou P. Utility of Ki-67, p53, Bcl-2, and Cox-2 biomarkers for low-grade endometrial cancer and disordered proliferative/benign hyperplastic endometrium by imprint cytology. Diagn Cytopathol. 2014;42(2):134-42. doi: 10.1002/dc.23010.
  • 10. Apostolou G, Apostolou N, Nikolaidou C, Kavantzas N, Patsouris E, Athanassiadou P. Cytodiagnosis of endometrial carcinoma and hyperplasia on imprint smears with additional immunocytochemistry using Ki-67 and p53 biomarkers. Cytopathol. 2014;25(2):86-94. doi: 10.1111/cyt.12095.
  • 11. Luukkaa H, Klemi P, Leivo I, Vahlberg T, Grenman R. Prognostic significance of Ki-67 and p53 as tumor markers in salivary gland malignancies in Finland: an evaluation of 212 cases. Acta Oncol. 2006;45(6):669-75. doi: 10.1080/02841860500543208. [PubMed: 16938809].
  • 12. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182(3):311-22. doi: 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9. [PubMed: 10653597].
  • 13. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133(4):1710-5. [PubMed: 6206131].
  • 14. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients. Breast. 2008;17(4):323-34. doi: 10.1016/j.breast.2008.02.002.
  • 15. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23(28):7212-20. doi: 10.1200/JCO.2005.07.501. [PubMed: 16192605].
  • 16. Koda M, Jarzabek K, Kanczugakoda L, Przystupa W, Tomaszewski J, Sulkowska M, et al. [Comparative studies of K1-67 expression between the primary tumor and breast cancer metastases to regional lymph nodes]. Ginekol Pol. 2003;74(9):754-60. Polish. [PubMed: 14674120].
  • 17. Wintzer HO, Zipfel I, Schulte‐Monting J, Hellerich U, von Kleist S. Ki‐67 immunostaining in human breast tumors and its relationship to prognosis. Cancer. 1991;67(2):421-8.
  • 18. Buxant F, Anaf V, Simon P, Fayt I, Noel JC. Ki-67 immunostaining activity is higher in positive axillary lymph nodes than in the primary breast tumor. Breast Cancer Res Treat. 2002;75(1):1-3. [PubMed: 12500929].
  • 19. Koda M, Sulkowski S, Kanczuga-Koda L, Surmacz E, Sulkowska M. Expression of ERα, ERβ and Ki-67 in primary tumors and lymph node metastases in breast cancer. Oncol Rep. 2004. doi: 10.3892/or.11.4.753.
  • 20. Suthipintawong C, Wejaranayang C, Vipupinyo C. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma. J Med Assoc Thai. 2008;91(12):1779-84. [PubMed: 19133508].
  • 21. Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med. 2010;1(5):747-54. doi: 10.3892/etm.2010.133.
  • 22. Inwald EC, Klinkhammer-Schalke M, Hofstadter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013;139(2):539-52. doi: 10.1007/s10549-013-2560-8. [PubMed: 23674192]. [PubMed Central: PMC3669503].
  • 23. Sahin AA, Ro JY, El‐Naggar AK, Ordonez NG, Ayala AG, Ro J, et al. Ki‐67 immunostaining in node‐negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer. 1991;68(3):549-57.
  • 24. Campani D, De Negri F, Fabbri R, Martini L, Giani C, Squartini F, et al. Estrogen, progesterone receptors and proliferating activity evaluated by immunocytochemistry in breast cancer. Int J Biol Markers. 1991;6(3):144-50. [PubMed: 1791308].
  • 25. Marchetti E, Querzoli P, Marzola A, Bagni A, Ferretti S, Fabris G, et al. Assessment of proliferative rate of breast cancer by Ki-67 monoclonal antibody. Mod Pathol. 1990;3(1):31-5. [PubMed: 2308919].
  • 26. Tamaki K, Ishida T, Tamaki N, Kamada Y, Uehara K, Miyashita M, et al. Analysis of clinically relevant values of Ki-67 labeling index in Japanese breast cancer patients. Breast Cancer. 2014;21(3):325-33. doi: 10.1007/s12282-012-0387-5. [PubMed: 22782361].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments